Search research articles
Contact Us
Filters
Showing results (331-340 of 373) with videos related to
Page
of 38
Sort By:
The Lancet. Oncology
|
February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Blood Advances
|
March 19, 2024
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis
Julia Driessen, Fer de Wit, Alex F Herrera, et al.
Journal of Hepatology
|
September 24, 2022
A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study
Andrew Fagan, Edith A Gavis, Mary Leslie Gallagher, et al.
Journal of Hepatology
|
January 12, 2025
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial
Jasmohan S Bajaj, Andrew Fagan, Edith A Gavis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2012
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials
Karolin Behringer, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology
|
August 28, 2015
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group
Paul J Bröckelmann, Helen Goergen, Michael Fuchs, et al.
JAMA Oncology
|
May 1, 2020
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
Paul J Bröckelmann, Helen Goergen, Ulrich Keller, et al.
Blood
|
September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Markus Dietlein, Jeremy Franklin, et al.
The American Journal of Gastroenterology
|
June 7, 2018
Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis
Jasmohan S Bajaj, Chathur Acharya, Andrew Fagan, et al.
Metabolic Brain Disease
|
March 5, 2014
Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis
Vishwadeep Ahluwalia, James B Wade, Douglas M Heuman, et al.
Page
of 38
Search research articles
Search
Showing results (331-340 of 373) with videos related to
Sort By:
Page
of 38
The Lancet. Oncology
|
February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Blood Advances
|
March 19, 2024
Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score-matched analysis
Julia Driessen, Fer de Wit, Alex F Herrera, et al.
Journal of Hepatology
|
September 24, 2022
A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study
Andrew Fagan, Edith A Gavis, Mary Leslie Gallagher, et al.
Journal of Hepatology
|
January 12, 2025
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial
Jasmohan S Bajaj, Andrew Fagan, Edith A Gavis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2012
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials
Karolin Behringer, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology
|
August 28, 2015
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group
Paul J Bröckelmann, Helen Goergen, Michael Fuchs, et al.
JAMA Oncology
|
May 1, 2020
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
Paul J Bröckelmann, Helen Goergen, Ulrich Keller, et al.
Blood
|
September 2, 2008
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe, Markus Dietlein, Jeremy Franklin, et al.
The American Journal of Gastroenterology
|
June 7, 2018
Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis
Jasmohan S Bajaj, Chathur Acharya, Andrew Fagan, et al.
Metabolic Brain Disease
|
March 5, 2014
Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis
Vishwadeep Ahluwalia, James B Wade, Douglas M Heuman, et al.
Page
of 38